| Literature DB >> 29323212 |
Subramaniyan Bharathiraja1, Nhat Quang Bui2, Panchanathan Manivasagan1, Madhappan Santha Moorthy1, Sudip Mondal1, Hansu Seo2, Nguyen Thanh Phuoc2, Thi Tuong Vy Phan2, Hyehyun Kim2, Kang Dae Lee3, Junghwan Oh4,5.
Abstract
Palladium, a near-infrared plasmonic material has been recognized for its use in photothermal therapy as an alternative to gold nanomaterials. However, its potential application has not been explored well in biomedical applications. In the present study,Entities:
Mesh:
Substances:
Year: 2018 PMID: 29323212 PMCID: PMC5764953 DOI: 10.1038/s41598-017-18966-8
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Figure 1(a) A scheme showing the preparation of Pd NPs and further surface coating with thiloated chitosan oligosaccharide (Pd@COS NPs) and finally functionalization using RGD peptide (Pd@COS-RGD). (b) A systematic illustration showing the photothermal ablation and photoacoustic imaging of tumor tissue using Pd@COS-RGD.
Figure 2(a) UV-Vis absorbance spectrum of Pd NPs, Pd@COS NPs, and Pd@COS-RGD dispersed in water. (b) TEM images of Pd NPs with different modifications along with SAED patterns. (c) The X-ray diffraction (XRD) patterns in the 2θ range 20–80° of initial Pd NPs and final Pd@COS-RGD. (d) FTIR spectrum of freeze-dried Pd NPs, Pd@COS NPs, and Pd@COS-RGD.
Figure 3(a) Heating curve of Pd@COS-RGD (50 ppm) dispersed in 1 mL of water and irradiated with an 808-nm laser at different power densities. (b) Thermal curves of Pd@COS-RGD at different concentrations under 808-nm laser illumination at 2 W cm−2 power density. (c) Thermal stability of Pd@COS-RGD (50 ppm) over 5 cycles of a laser on/off experiment at 2 W cm−2 power density. (d) Optical absorbance spectrum of Pd@COS-RGD before and after 5 cycles of a laser on/off experiment.
Figure 4(a) In vitro cytotoxicity or biocompatibility of as-synthesized Pd NPs, COS-coated Pd NPs (Pd@COS NPs), and RGD-conjugated Pd@COS-RGD using the MTT assay. (b) Quantitative analysis of internalization of Pd@COS NPs and Pd@COS-RGD by MDA-MB-231 cells at different time intervals. (c) Viability of MDA-MB-231 cells incubated with or without Pd@COS-RGD (50 ppm) after 24 h of laser therapy using an 808-nm laser at different power densities. (d) In vitro photothermal cytotoxic effects of Pd@COS NPs and Pd@COS-RGD on MDA-MB-231 cells irradiated with 808-nm laser at 2 W cm−2 for 5 min. (e) Fluorescent images of MDA-MB-231 cells using AO/PI at different conditions and the concentration of Pd@COS-RGD fixed to be 50 ppm (green- live cells, red- dead cells). All data are presented as the mean ± standard deviation of three independent experiments (*p < 0.05, significant; **p < 0.01, highly significant).
Figure 5(a) In vivo tumor accumulation of Pd@COS NPs and Pd@COS-RGD at different time intervals. (b) Biodistribution of Pd@COS NPs and Pd@COS-RGD in major mice organs and tumor after 24 h of intravenous injection. The Pd metal concentration was analyzed using ICP-MS. The data are presented as the mean ± standard deviation (*p < 0.05, significant).
Figure 6Infrared thermograph of MDA-MB-231 breast tumor-bearing nude mice irradiated with 808-nm laser at 2 W cm−2 after 1 h of intravenous injection of PBS and Pd@COS-RGD.
Figure 7Photograph of MDA-MB-231 tumor-bearing mouse on 0 and on the 20th day of observation after intravenous injection of PBS and Pd@COS-RGD (5 mg/kg). The 808-nm laser irradiated the tumor region for 5 min at 2 W cm−2 power density after 1 h of intravenous injection.
Figure 8(a) Tumor growth curves of different groups of MDA-MB-231 tumor-bearing mice normalized against initial tumor volume. (b) The mean body weight of different groups of animals over 20 days after treatment. Data are presented as the mean ± standard deviation.
Figure 9(a) Top view of tissue-mimicking phantom loaded with Pd@COS-RGD treated and untreated control MDA-MB-231 cell inclusions. in vitro photoacoustic imaging of control and treated cells using 808-nm laser represented with 2D (b) and 3D images (c). (d) In vivo photoacoustic imaging of MDA-MB-231 tumor-bearing mice before and after 1 h of tail vein injection of Pd@COS-RGD.